linjc16/ctgov huggingface dataset:
A Multi-center Study on Human Microecology Assisted Diagnosis of Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
As for this research，we want to find whether the intestinal microecology (flora, peptidoglycan fragments) have certain distribution characteristics in colorectal diseases; whether it can predict the development of disease/as a prognostic indicator.

Detailed Description
-----------------
We even want to find whether it can predict the development of disease/as a prognostic indicator.

Official Title
-----------------
A Multi-center Study on Human Microecology Assisted Diagnosis of Colorectal Cancer

Conditions
-----------------
Human Microecology；Colorectal Disease；Auxiliary Diagnosis

Intervention / Treatment
-----------------
* Other: observe only


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: people who is going to get the colonoscopy examination Exclusion Criteria: people who was diagnosed as one cancer，expect for CRC; who has had the antibiotics or the medicine that treats for colorectal disease, except for medical probiotics, in one month; who has had the laxative and the colonscopy in one week; who had a operation in three month.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Colorectal Cancer(CRC)<br>People who is diagnosed with CRC by colonoscopy and pathological biopsy | Other: observe only<br>* observe only<br>|
| Inflammatory Bowel Disease<br>People who is diagnosed with IBD by colonoscopy and pathological biopsy | Other: observe only<br>* observe only<br>|
| Colorectal adenoma(CRA)/adenomatous polyposis<br>People who is diagnosed with CRA by colonoscopy and pathological biopsy | Other: observe only<br>* observe only<br>|
| Non-adenomatous polyps<br>People who is diagnosed with non-adenomatous polyps by colonoscopy and pathological biopsy | Other: observe only<br>* observe only<br>|
| Irritable bowel syndrome<br>People who is diagnosed with IBS by colonoscopy and pathological biopsy | Other: observe only<br>* observe only<br>|
| normal<br>People who has no obvious abnormality in the whole colon | Other: observe only<br>* observe only<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| collect specimen before colonscope | collect fecal，saliva，urine，blood to assess the level of the activation of NOD2，cytokines | Baseline (before colonscope) |
Suppressive Antibiotic Therapy for Endocarditis

Study Overview
=================
Brief Summary
-----------------
Endocarditis are deadly infections, which nowadays occurs mainly among older patients with multiple comorbidities. The incidence is notably high among patients with valvular prosthetic or implantable devices. Management of such situation usually requires intravenous antibiotic therapy along with removal of the infected prosthetic or device. However, such invasive procedures and revision surgeries may be judged unreasonable among these patients, who are then exposed to a high risk of infectious relapse when curative antibiotics are discontinued. In these situation, a long-course antibiotic therapy may be used in order to maintain lasting infection control, to limit the risks of relapse of infection due to the infected device retention, and ultimately to prolong survival. This strategy is already suggested in case of infected prosthesis joint retention (IDSA 2013), and has been proposed for implantable device retention by the American Heart Rhythm Society in 2017, but data regarding its modalities and outcomes are scare. The objectives of this study are to describe the survival of patient under long-term antibiotic therapy for endocarditis, at 6-months and 1 year after initiation. Secondary outcomes includes modalities of the suppressive treatment prescribed, its security (secondary effects, tolerance) and to precise causes of death.

Official Title
-----------------
Suppressive Antibiotic Therapy for Prosthetic Valve or Implantable Device Related Infectious Endocarditis

Conditions
-----------------
Endocarditis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Major subject (≥18 years old) Subject having benefited from suppressive antibiotic therapy after collegial decision in CPR Endocarditis during the period from January 1, 2016 to January 31, 2023 Subject not opposing the reuse of their data for the purposes of this research. Exclusion criteria: Subject having expressed opposition to participating in the study Death or loss of sight of the patient before initiation of suppressive antibiotic therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival of the patient who benefited from suppressive antibiotic therapy |  | Survival at 6 months, 1 year, 3 years after infection | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endocarditis, Antibiotic therapy, Suppressive antibiotics, Long term treatment
Discovering Trends in Chronic Fatigue Syndrome Patients' Clinical Study Experiences

Study Overview
=================
Brief Summary
-----------------
The study seeks to delve into the firsthand experiences of patients diagnosed with chronic fatigue syndrome who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. The data collected from this study will help improve future outcomes for all chronic fatigue syndrome patients as well as those in under-represented demographic groups.

Official Title
-----------------
Assessing Patient Engagement and Understanding in Chronic Fatigue Syndrome Clinical Trials

Conditions
-----------------
Chronic Fatigue Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed Written Informed Consent Aged ≥ 18 years old No prior treatment for chronic fatigue syndrome Exclusion Criteria: Participant is actively receiving study therapy in another Inability to provide written informed consent Women of childbearing potential without a negative pregnancy test; or women who are lactating.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to join in a chronic fatigue syndrome clinical trial |  | 3 months | 
| Number of chronic fatigue syndrome patients who remain in clinical trial until completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Fatigue Syndrome
Asan Medical Center CCTA Registry

Study Overview
=================
Brief Summary
-----------------
A total of 9269 adults who received CCTA scans for coronary disease evaluation during a general medical checkup at the Health Screening and Promotion Center in Asan Medical Center, Seoul, Korea between January 2007 and December 2011 were initially selected. All participants were provided with information about the potential benefits and risks of CCTA and made the decision to undergo the procedure at their own expense. They were also informed that their clinical and radiological data would be used for this study and gave their consent. Of these individuals, 7129 agreed to participate, and 6343 were enrolled in this CCTA registry.

Official Title
-----------------
Assessment of Coronary Artery Disease in Asymptomatic Population Undergoing Coronary Computed Tomography Angiography: A Single Center, Prospective Observational Study

Conditions
-----------------
Coronary Artery Disease, Risk Factor, Computed Tomography

Intervention / Treatment
-----------------
* Diagnostic Test: Coronary CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Exclusion Criteria: a previous history of angina or myocardial infarction; abnormal rest electrocardiographic results, i.e., pathological Qwaves, ischemic ST segments or T wave changes, or left bundle-branch blocks; insufficient medical records; structural heart diseases; a prior history of open heart surgery or percutaneous coronary intervention; a previous cardiac procedure; or renal insufficiency (creatinine N1.5 mg/dL)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Coronary CT|Coronary CT evaluation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prevalence of CAD | Diameter stenosis >50% in any coronary artery by coronary CT angiography | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality |  | 5 years | 
| cardiovascular mortality | any death caused by a cardiovascular problem or if there was no identified cause of death | 5 years | 
| myocardial infarction | Number of participants with an increase in cardiac enzyme above the upper reference limit with ischemic symptoms or signs. | 5 years | 
| Revascularization | Number of participants with any percutaneous or surgical revascularization procedure during follow-up. | 5 years |
Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU

Study Overview
=================
Brief Summary
-----------------
Multicenter retrospective study conducted in the intensive care units of Tourcoing, Roubaix, and Lille hospitals. Patients hospitalized in the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU will be selected from microbiology laboratory data. Patient demographics and clinical data will be collected from the medical record. Microbiological results will be collected from the laboratory data.

Detailed Description
-----------------
INCLUSION CRITERIA - Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU. PRIMARY ENDPOINT - The primary endpoint is 30-day mortality.

Official Title
-----------------
Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU

Conditions
-----------------
Drug Resistance, Multiple, Bacterial

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU. Exclusion Criteria: Patient who is a minor, protected adult, or who refuses to participate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint is all-cause 30-day mortality. | all-cause mortality. | 30-day mortality | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adequacy of initial antibiotic therapy to french recommendations | Antibiotic prescriptions will be considered adequate if all of the following criteria meet the recommendations: molecule, dose, according to the recommendations provided by the French Society of Infectious Diseases. The recommendations for prescribing antibiotics are similar to those proposed by international guidelines. | adequate within 30 days |
Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet

Study Overview
=================
Brief Summary
-----------------
Anaphylactic shock is the most severe expression of immediate hypersensitivity reactions. The mechanisms leading to these reactions are still poorly understood and may involve platelets, especially in the most severe forms. The IgE ( ImmunoglobulineE)-mediated mechanism, involving the FcERI(the high-affinity receptor for the Fc region of immunoglobulin E (IgE) receptor present on the surface of mast cells and basophilic cells, is the most common mechanism. The receptors FcERI and FcERII are also described as being present on the surface of blood platelets, which would imply their activation along with the other cells involved. However, studies showing the presence of the FcERI/RII receptors on blood platelets suffer from many biases. The main objective of the research is to study whether the FcERI/RII receptors are present and functional on the surface of blood platelets from allergic patients.

Official Title
-----------------
Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet

Conditions
-----------------
Allergy

Intervention / Treatment
-----------------
* Other: Flow cytometry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years-old With a protein/drug allergy (hymenoptera, arachide, amoxicillin) Confirmed by skin tests and/or challenge test With specific IgEs Exclusion Criteria: Patients who refuse to participate to this study Patients unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Flow cytometry|Analysis of blood samples from a health sample's allergic patients and analysis with flow cytometry|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of functionnal FcERI/RII receptors on the surface of blood platelets from allergic patients | After confirmation of the allergy by a well conducted allergy workup | 1 day |
Survey of Symptoms After a COVID Vaccination in Employees

Study Overview
=================
Brief Summary
-----------------
Background: SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) has had us firmly in its grip for more than two years. In January 2021, the quality and risk management unit of the LKH (Landeskrankenhaus) -Univ. Klinikum Graz commissioned to carry out vaccinations for employees and subsequently for high-risk patients. In the vaccination line, which was open for 85 days in 2021/22, the vaccines from Astra Zeneca, Biontech-Pfizer and Moderna were vaccinated. There were hardly any complications. The primary immunization, booster vaccination and booster vaccination were carried out. Despite the small number of incidents in the sense of an immediate reaction, there were numerous sick leave. Methods: For this reason, in the course of the booster vaccination, starting from October 2021 to January 2022, every vaccinated person was asked to fill out a questionnaire. Participation was voluntary and was supported by the works councils of the Medical University and the LKH-University clinic Graz approved. The survey served to retrospectively record how many employees developed symptoms in response to the respective vaccination. With this approach it will be possible to subject the responses to an in-depth statistical analysis in order to obtain a data-based contribution to the side effects of vaccines categorized with different vaccination schemes.

Official Title
-----------------
Survey of Symptoms After a COVID Vaccination in Employees: a Retrospective Study.

Conditions
-----------------
Symptoms Recoding SARS-CoV-2 After Vaccination

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Employees with appropriate indication (>4 months after the second vaccination) according to the recommendations of the national vaccination committee. Signed vaccination information sheet. Exclusion Criteria: no booster vaccination.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|questionnaire|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of symptoms after the respective vaccination | Occurence of symptoms, assessed by a questionnaire | 10 Minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-CoV-2, Symptoms
Serum Lipase and Severity of Pancreatic Injury.

Study Overview
=================
Brief Summary
-----------------
Diagnosis of pancreas injury is not easy at first consult. It's a retrospective study, in children under 15 years and 3months, between January 1st 2010 to August 31th 2019, to prove that the first level of lipase is correlated with the severity of pancreatic injury. Every children with elevated serum lipase after trauma during those years will be selected. The children with pancreatic tumors will be excluded. American Association of Surgeon Trauma (AAST) classification of pancreas injury will be used to grade severity. Children will be divided in two groups : one including pancreatic lesion with duct injury and one without duct injury. Data will include mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications will be noted.

Detailed Description
-----------------
The main objective of this study is to determine if there is a correlation between the initial serum lipase and the severity of the pancreatic injury.

Official Title
-----------------
Serum Lipase and Severity of Pancreatic Injury.

Conditions
-----------------
Pancreatic Injury

Intervention / Treatment
-----------------
* Other: data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children under 15 years 3 months with elevated lipase serum level after trauma. Exclusion Criteria: Elevation of lipase secondary to pancreatic tumor

Ages Eligible for Study
-----------------
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Every children with elevated serum lipase<br>Every children with elevated serum lipase after trauma during those years will be included. | Other: data collection<br>* data collection : mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lipase level in severe pancreatic injury (duct injury) | Collected in medical history. | Month: 9 (end of study) | 
| lipase level in light pancreatic injury (without duct injury) | Collected in medical history. | Month: 9 (end of study) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Local complications | Collected in medical history. | Month: 9 (end of study) | 
| Maximal lipase level | Collected in medical history. | Month: 9 (end of study) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lipase, Pancreatic trauma, Pseudocysts
Comparison of AT & PR Training to Improve Functional Ability After Breast Cancer Surgery

Study Overview
=================
Brief Summary
-----------------
To determine the effect of aerobic training and progressive resistance training to improve upper limb functional ability after breast cancer surgery

Official Title
-----------------
Comparison of Aerobic Training and Progressive Resistance Training to Improve Functional Ability After Breast Cancer Surgery

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Aerobic Training
* Diagnostic Test: Progressive Resistance Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a) Breast cancer female survivors eligible under 35-65 years complaining of cancer-related fatigue. b) Adjunctive radiotherapy or underwent surgery (lumpectomy or mastectomy), willing to participate will be included in the study. c) Shoulder pain d) Decreased ROM e) Primary unilateral BC, ALND, no distant metastases, no previous ALND on the contra lateral side f) No previous history of arm lymph edema Exclusion Criteria: - a) Survivors with other concurrent metastasis anywhere else in the body, diagnosed case of any cardiac or respiratory condition, contra-indicated for exercise training (severe dyspnea, chest pain, severe nausea, ataxia, dizziness etc.) b) Any other neurological or recent musculoskeletal problems were excluded from the study. c) Bilateral mastectomy d) Adjunctive chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Aerobic Training<br> | Diagnostic Test: Aerobic Training<br>* Aerobic Training to Improve Functional Ability After Breast Cancer Surgery<br>|
| Experimental: Progressive Resistance Training<br> | Diagnostic Test: Progressive Resistance Training<br>* Progressive Resistance Training to Improve Functional Ability After Breast Cancer Surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numerical pain rating scale (NPRS) |  | 6 Months | 
| Goniometer Tool |  | 6 Months |